Activist investor Bill Ackman broke all of his personal investment rules when he bet big on Valeant Pharmaceuticals. And now he’s calling the move “one very big mistake.”
As the Pershing Square Capital Management chief told CNBC’s “Squawk Box,” he “went off the reservation” with the Canadian drugmaker.
“We never normally get to meet the management of a company before making an investment. [And] we never invest in really complicated companies you can’t figure out from just reading the 10-K [filing],” he said.
But those standards went out the window when Ackman and then-Valeant head honcho J. Michael Pearson joined forces to make a hostile play for Allergan in 2014, and Ackman continued to up his Valeant stake even in the wake of the buyout quest’s failure.
Of course, Valeant has since come crashing down, thanks to channel-stuffing allegations, pricing pushback and debt-default concerns–and Ackman has paid the price. He called the past 12 months the “worst period of performance” of his investment career, placing the blame squarely on Valeant’s downward spiral.
Those who played large roles in advising Ackman to take a chance on the Quebec-based drugmaker? They’ve paid it, too. Friday, Ackman said analyst Jordan Rubin–the last remaining player who had worked closely on the investment–was set to depart Pershing Square, Reuters reported.
Ackman, though, is still doing what he can to right the ship, and toward that end, he took on a more active role this March when he assumed a director position on Valeant’s board. And with a handful of changes already made to the company’s leadership–including the hiring of new CEO Joseph Papa, formerly the skipper at Perrigo, and of CFO Paul Herendeen, a Zoetis veteran–he thinks the company is in better shape than it was.
At the very least, Valeant now looks like a “more traditional Pershing Square investment” now that it’s taken a beating, he said.
“We normally invest when shareholders have lost confidence in management,” he told CNBC. “And that’s what happened here.”
By Carly Helfand
Source: Fierce Pharma
Airnov provides critical healthcare industries with high-quality, controlled atmosphere packaging, to protect their products from moisture and oxygen. The business has manufacturing facilities in the USA, France, China and India and employs around 700 people.
Takeda of Japan has partnered with Hong Kong-based Hutchmed, gaining the commercial rights to colorectal cancer drug fruquintinib outside of China for $400 million up front, plus $730 million in potential milestone payments. Takeda also will help develop fruquintinib, which can be applied to subtypes of refractory metastatic colorectal cancer, regardless of biomarker status, the companies said.
On April 3, Scangos, who’s been chief executive officer at Vir since the start of 2017, will hand over the reins to Marianne De Backer, Ph.D. De Backer comes over from Bayer, where she currently heads up pharmaceutical strategy, business development and licensing. Alongside her CEO appointment, De Backer is set to join Vir’s board of directors, the company said Wednesday.